瑞德西韦（GS-5734）通过抑制病毒RNA合成来阻碍肠道病毒复制。
Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition.
作者信息
Ye Wei, Yao Min, Dong Yangchao, Ye Chuantao, Wang Dan, Liu He, Ma Hongwei, Zhang Hui, Qi Libin, Yang Yuewu, Wang Yuan, Zhang Liang, Cheng Linfeng, Lv Xin, Xu Zhikai, Lei Yingfeng, Zhang Fanglin
机构信息
Department of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
出版信息
Front Microbiol. 2020 Jun 12;11:1105. doi: 10.3389/fmicb.2020.01105. eCollection 2020.
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense and and negative-sense , , and . Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.
人肠道病毒可引发多种疾病，从轻微的呼吸道症状到致命的神经并发症。目前，尚无已注册的抗病毒药物被批准用于临床治疗。因此，迫切需要一种针对肠道病毒相关疾病的治疗药物。瑞德西韦（GS-5734）是一种新型的单磷酸酰胺腺苷类似物前药，对多种RNA病毒家族具有强大的抗病毒活性，包括正链和负链的、、和。目前，瑞德西韦正处于用于治疗COVID-19疾病的3期临床开发阶段。在此，我们发现瑞德西韦可阻碍肠道病毒71型（EV71）的病毒RNA（vRNA）和互补RNA（cRNA）合成，这表明瑞德西韦的三磷酸（TP）形式可抑制EV71复制。此外，瑞德西韦对多种肠道病毒显示出强大的抗病毒活性。这些数据将瑞德西韦的抗病毒活性扩展至肠道病毒，并表明瑞德西韦是治疗EV71和其他肠道病毒感染的一种有前景的抗病毒药物。
Zotero 插件